Hookipa Pharma is a biopharmaceutical company focused on developing innovative therapies for cancer and viral infections
The company utilizes its proprietary virus-enhanced immunotherapy platform to create treatments that harness and boost the immune system's natural ability to fight disease. By advancing its pipeline of targeted therapeutic candidates, Hookipa aims to improve patient outcomes and provide new options for individuals afflicted with challenging health conditions. Their approach emphasizes both the development of personalized medicine and the exploration of novel therapeutic mechanisms to address unmet medical needs.
HOOKIPA Pharma secures FDA clearance for its innovative HB-700 therapeutic vaccine targeting KRAS-mutated cancers. Learn about its broad impact on lung, colorectal, and pancreatic cancers, achieving significant milestones in collaboration and intellectual property.
Roche study results show prolonged survival in R/R diffuse large B-cell lymphoma patients treated with Columvi (glofitamab) + GemOx vs. Rituxan + GemOx.
Each week, Benzinga’s Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the surface and warrant attention.
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 100 points on Thursday. The Dow traded up 0.37% to 37,218.15 while the NASDAQ rose 0.73% to 14,885.76. The S&P 500 also rose, gaining, 0.50% to 4,721.72.
